Hosp Univ Vall D Hebron

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Hepatitis B4 trials
• Multiple myeloma3 trials
• Depression2 trials
• Hodgkin lymphoma2 trials
• Myelodysplastic syndromes2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Epilepsy1 trial
• Head and neck cancer1 trial
• High blood pressure1 trial
• and 6 more

Phase

• Phase 28 trials
• Phase 38 trials
• Phase 13 trials

Status

• Completed14 trials
• Recruiting4 trials
• Active, not recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC17 trials
• Actelion1 trial
• Janssen Pharmaceutica N.V., Belgium1 trial
• Johnson & Johnson Enterprise Innovation Inc.1 trial

Running trials

• Recruiting

  A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

  NCT07586202· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

  NCT05275023· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

  NCT05123599· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

  NCT04882878· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

  NCT04836559· Phase 2· Janssen Research & Development, LLC· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

  NCT04657224· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

  NCT04535544· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT03904693· Phase 3· Actelion· Source

• Completed

  A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

  NCT03573310· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Janssen Research & Development, LLC· Source